Table 2.
Influences of genetic polymorphisms with pregnancy characteristics in patients negative on every test for SARS-CoV-2 (A) and patients with at least one positive on a test for SARS-CoV-2 (B) (E3 = estriol; AFP = alpha-fetoprotein; NT = nuchal translucency; ABD-C = abdominal circumference; FFL = fetal femur length; MAL = malformations; GD = gestational diabetes; AB = abortion; LRF DNA GD = low risk fetal DNA for genetic disease; AMNIO = amniocentesis; PTB = preterm birth).
| p-Values for Patients Negative for Every Test for SARS-CoV-2 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | E3 | AFP | NT | ABD-C | FFL | MAL | GD | AB | LRF DNA GD | AMNIO | PTB |
| VDR Taq I (TC_CC) | 0.02 | 0.003 | |||||||||
| VDR Taq I (CC) | 0.02 | ||||||||||
| VDR ApaI (CA_AA) | 0.03 | ||||||||||
| VDR FokI (CC) | 0.03 | ||||||||||
| VDR FokI (TC_CC) | 0.04 | ||||||||||
| VDR BsmI (AA) | 0.01 | ||||||||||
| VDR BsmI (GA_AA) | 0.03 | ||||||||||
| VDBP GC1296 (AC_CC) | 0.04 | ||||||||||
| CYP27A1 345 (GG) | 0.02 | ||||||||||
| CYP24A1 3999 (CC) | 0.03 | ||||||||||
| CYP24A1 22776 (TT) | 0.05 | ||||||||||
| B | p-Values for Patients with at Least One Positive Test for SARS-CoV-2 | ||||||||||
| CYP27B1 −1260 (TT) | 0.03 | ||||||||||
| CYP24A1 22776 (CT_TT) | 0.02 | ||||||||||
| VDR ApaI (AA) | 0.03 | 0.01 | 0.03 | ||||||||
| VDR FokI (CC) | 0.04 | ||||||||||
| CYP24A1 8620 (AG_GG) | 0.05 | ||||||||||
| CYP24A1 8620 (GG) | 0.01 | ||||||||||
| CYP27A1 345 (AG_GG) | 0.04 | ||||||||||
| CYP24A1 22776 (TT) | 0.01 | ||||||||||